Statin Therapy-Evidence Beyond Lipid Lowering Contributing to Plaque Stability

$63.00 plus tax (Refund Policy)

Buy Article:

Abstract:

Primarily statin drugs inhibit hepatic 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA)reductase, which is responsible for the reduction in circulating low-density lipoprotein (LDL) cholesterol.Several findings from recent research studies indicate that statins have multiple actions that favorablyinfluence key factors involved in the atherogenic process. These so-called pleiotropic properties affect variousaspects of cell function, inflammation, coagulation, and vasomotor activity. These effects are mediated eitherindirectly through LDL cholesterol reduction or via a direct effect on cellular functions. Such actions maycontribute to the early cardiovascular benefit observed in several outcome trials with statin drugs therapy.Although many of the pleiotropic properties of statins may be a class effect, some may be unique to certainagents and account for differences in their pharmacological activity.

This review summarise the results of the major outcome trials of statins and non-statins therapy and thepossible mechanisms beyond lipid lowering contributing to plaque stability.

Keywords: Statins; coronary heart disease; lipid lowering agents; plaque stability; pleiotropic effects; thrombosis

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986706779010324

Affiliations: Consultant Physician in General Medicine & Prevention of Vascular Disorders, ThrombosisResearch Institute, 1 B Manresa Road, London SW3 6LR, UK.

Publication date: December 1, 2006

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more